• 제목/요약/키워드: Qingfei Paidu

검색결과 3건 처리시간 0.022초

COVID-19에 대한 청폐배독탕의 연구 동향 분석 (The Effects of Qingfei Paidu Decoction on Coronavirus Disease-19: A Narrative Review)

  • 강보형;최유경;전찬용;양승보
    • 대한한방내과학회지
    • /
    • 제41권3호
    • /
    • pp.424-433
    • /
    • 2020
  • Qingfei Paidu decoction is recommended for treatment and prevention of COVID-19. It is a prescription that combines Mahaenggamseok-tang, Oryeong-san, Soshiho-tang, Saganmahwang-tang, and Kwakhyangjeonggi-san. According to several clinical reviews, symptoms of COVID-19 were improved, laboratory test indicators were improved, and the cure rate was increased. Pharmacologically, the Qingfei Paidu decoction and its composition have been reported to inhibit viral replication, alleviate immune responses, and have anti-inflammatory and antiviral effects. Severe side effects were not revealed, and this treatment is considered relatively safe. However, to validate and better understand these findings, well-designed clinical studies are needed.

청폐배독탕 및 청폐배독탕거마황을 사용해 COVID-19 증상의 개선을 보인 증례 보고 : 후향적 사례군연구 (Treating COVID-19 with Qingfei Paidu Decoction with and without Ephedra Herba: A Retrospective Case Series)

  • 김광호;강건희;이영웅;강선이;지상호;송주환;김철현;이상관
    • 대한한방내과학회지
    • /
    • 제43권2호
    • /
    • pp.264-273
    • /
    • 2022
  • The purpose of this report is to describe the effects of Qingfei Paidu decoction (QPD) and QPD without Ephedra Herba on COVID-19 patients. One COVID-19 patient was treated with QPD and two others who had been sensitive to ephedra were treated with QPD without it. The fever, cough, and sore throat of all three were monitored three times a day through non-face-to-face assessment for a total of five to seven days, and cough and throat pain changes were evaluated with a numeric rating scale (NRS). After treatment, the fever and NRS scores were improved for all three patients. These results indicate that both QPD and QPD without Ephedra Herba is an effective treatment for COVID-19 symptoms.

Management of asymptomatic to mild COVID-19 patients with Cheongpebaedok-tang on the telemedical basis: A retrospective observational case series

  • Sung-Woo Kang;Kwan-Il Kim;Mideok Song;Jinhwan Roh;Namhun Cho;Heung Ko;Sung-Se Son;Minjeong Jeong;Jun-Yong Choi;Ojin Kwon;Seojung Ha;Hee-Jae Jung;Beom-Joon Lee
    • 대한한의학회지
    • /
    • 제44권4호
    • /
    • pp.41-58
    • /
    • 2023
  • Objectives: This retrospective observational study aimed to investigate the efficacy and safety of Cheongpebaedok-tang, a traditional Korean herbal medicine, provided via telemedicine to patients with asymptomatic to mild COVID-19 in Korea. Methods: From February to April 2020, a retrospective analysis investigated COVID-19 patients treated via Korean telemedicine. The study involved asymptomatic to mild cases receiving Cheongpebaedok-tang more than three times, along with continuous Korean medicine care in convalescence. Diagnoses and treatment adhered to the telemedicine guidelines of the Association of Korean Medicine, with varied Cheongpebaedok-tang prescriptions based on symptom severity. Symptom evaluation involved a detailed assessment using a 15-item tool at initial and final sessions. Results: The study included 27 patients, with a mean age of 48.7 ± 2.3 years (mean ± standard error). Patients began self-administering oral Cheongpebaedok-tang for an average of 19.4 ± 1.8 days after the date of COVID-19 diagnosis confirmation and continued the medication for 15.8 ± 1.2 days. The reported side effects of the Cheongpebaedok-tang included palpitations (11.1%), insomnia (7.4%), dizziness (3.7%), and diarrhea (3.7%). All side effects disappeared after adjusting the prescription according to standard treatment guidelines. The occurrence of all COVID-19-related adverse symptoms, except fatigue and myalgia, decreased. Fatigue was the most common chronic symptom persisting after 6 months (51.9%), followed by ocular symptoms (37.0%) and sore throat (22.2%). Conclusions: This study implies Cheongpebaedok-tang may offer a potentially safe, symptom-alleviating approach for managing mild COVID-19 cases via telemedicine, although further comprehensive research is warranted.